Clincosm LogoSign in Get a demo

Study on AUNIP as a Novel Tumor Marker for Cervical Cancer

Sponsor
Lin Yuan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06118463
Collaborator
(none)
300
Enrollment
60
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Detection of serum AUNIP expression

Detailed Description

Blood of all study participants of cervical cancer patients are collected to detect the expression of AUNIP, analyze the statistical correlation between the expression of cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily understand the expression of AUNIP in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Oct 1, 2027
Anticipated Study Completion Date :
Jan 1, 2029

Arms and Interventions

Arm Intervention/Treatment
study group

Women aged 20-60; There is a definite pathological diagnosis of cervical cancer

Diagnostic Test: Detection of serum AUNIP expression
The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
Healthy control group

Women aged 20-60; No tumors in the uterus or other parts of the body; No inflammatory disease; Blood routine and blood biochemical tests are normal.

Diagnostic Test: Detection of serum AUNIP expression
The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.

Outcome Measures

Primary Outcome Measures

  1. AUNIP expression in serum [through study completion, an average of 3 year]

    Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Study group inclusion criteria:

  • Women aged 20-60

  • There is a definite pathological diagnosis of cervical cancer

Healthy control group:

  • Women aged 20-60

  • No tumors in the uterus or other parts of the body

  • No inflammatory disease

  • Blood routine and blood biochemical tests are normal

Exclusion Criteria:
Exclusion criteria of the study group:
  • There are other lesions in the uterus and uterine adnexa
Exclusion criteria of healthy control group:

  • Pregnant, lactating or menarche women

  • Women who are undergoing human papillomavirus (HPV) vaccination

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Lin Yuan

Investigators

  • Principal Investigator: Lin Yuan, Ph.D., Qianfoshan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lin Yuan, Principal Investigator, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT06118463
Other Study ID Numbers:
  • yl20231001
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Uterine Cervical Neoplasms

Study Results

No Results Posted as of Nov 9, 2023